- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about CMPS
Recent news which mentions CMPS
Tickers
CMPS
From Motley Fool
Tickers
CMPS
From InvestorPlace
Jim Cramer Slams Political Blocking Of 'LSD-Derived Antidepressants,' Citing Strong Test Data 'Showing They Worked'
April 19, 2024
From Benzinga
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
April 17, 2024
From Benzinga
From Benzinga
From Benzinga
From Benzinga
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
March 29, 2024
From Benzinga
Atai Life Sciences Q4 And Full-Year 2023 Results: Steep Cash Drain Yet 2026 Target Remains, Update On Psychedelic Pipeline
March 29, 2024
From Benzinga
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
March 20, 2024
From Benzinga
From Benzinga
From Benzinga
Psychedelics 2024: Veterans Blessing, Mental Health Paradigm Shift, Providers Training, Ketamine-MDMA Bonds & More
March 06, 2024
From Benzinga
From Motley Fool
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
March 04, 2024
From Benzinga
Compass Pathways Plc (CMPS) Q4 2023 Earnings Call Transcript
February 29, 2024
Tickers
CMPS
From Motley Fool
Compass Pathways Shows Robust 2023 Year-End Results, Embraces Clinical Milestones For Psilocybin As Depression Treatment
February 29, 2024
Tickers
CMPS
From Benzinga
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
February 29, 2024
From Benzinga
Podcast - Post-Frenzy Psychedelics Investing And Reclaiming The Right To Pursue Happiness With Zappy Zapolin: '2024 Is When It Goes Mainstream'
February 29, 2024
From Benzinga
Earnings Scheduled For February 29, 2024
February 29, 2024
From Benzinga
Penny Power Players: 3 Stocks to Watch in the Microcap Arena
February 27, 2024
From InvestorPlace
Mental Health Mavericks: 3 Stocks Changing the Game
February 21, 2024
From InvestorPlace
Wall Street Says Compass Pathways Could Rise 307%. Here's How It Could Actually Happen.
February 19, 2024
Tickers
CMPS
From Motley Fool
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
February 15, 2024
From Benzinga
Why Is MindMed (MNMD) Stock Up 8% Today?
February 12, 2024
From InvestorPlace
Psilocybin Mushrooms For Sale: Is It Legal Anywhere In America?
February 02, 2024
Tickers
CMPS
From Benzinga
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
January 27, 2024
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.